Market Overview

Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS

Related TKPYY
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging
Amgen's Kyprolis regimen comes up short in late-stage study in certain multiple myeloma patients (Seeking Alpha)

The Takeda Oncology Company, a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited (OTC: TKPYY), and Seattle
Genetics (NASDAQ: SGEN) today announced the initiation of an
international phase 3 clinical trial evaluating ADCETRIS (brentuximab
vedotin) as part of a frontline combination chemotherapy regimen in
patients with previously untreated advanced Hodgkin lymphoma (HL). The
trial is being conducted under a Special Protocol Assessment (SPA)
agreement from the U.S. Food and Drug Administration (FDA) and the trial
also received scientific advice from the European Medicines Agency
(EMA). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a
defining marker of classical HL.

“Millennium is pleased to announce

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (SGEN + TKPYY)

View Comments and Join the Discussion!